What is CONMED Corporation's earnings per share (EPS)?

CONMED Corporation (CNMD) reported diluted earnings per share of $1.51 for fiscal year 2025. This represents a -64.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CONMED Corporation (CNMD) Financials

CNMD

FY2025 annual

Revenue $1.4B +5.2% YoY

Net Income $47.1M -64.4% YoY

EPS (Diluted) $1.51 -64.5% YoY

Free Cash Flow $150.9M -2.0% YoY

Market Cap $1.4B as of Sep 15, 2026

Price / Sales 1.0x on $1.4B revenue, FY2025

Price / Earnings 29.9x on $47.1M net income, FY2025

Price / Book 1.4x on $1.0B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 29, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CNMD SEC filings page.

CONMED Corporation (CNMD) reported $1.4B in revenue for fiscal year 2025, up 5.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CNMD FY2025 2026-08-30

CONMED’s dominant mechanic is revenue growth being absorbed by overhead in FY2025, while cash generation remains far steadier than reported earnings.

Operating cash flow was 3.6x net income in FY2025 versus 1.3x in FY2024, while free cash flow stayed near its prior-year level; the earnings shock therefore did not translate into comparable cash deterioration. That pattern makes cash flow a more representative read of operating throughput than the income statement alone, without proving why profit fell.

Revenue rose 5.2% while gross margin held near 55.0%, indicating the squeeze was not primarily a deterioration in production economics. Operating margin fell from 15.3% to 7.5% as SG&A expanded faster than sales, showing that overhead absorbed much of the additional gross profit.

Balance-sheet deleveraging continued: debt-to-equity declined from 0.9x to 0.8x as long-term debt fell, so expansion was funded less by borrowing. Current ratio eased from 2.3x to 2.1x, while positive free cash flow remained well above capital expenditures, combining a still-liquid posture with limited reinvestment drag.

Financial Health Signals

Financial Health Score 53/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of CONMED Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

CONMED Corporation has an operating margin of 7.5%, meaning the company retains $7 of operating profit per $100 of revenue. This strong profitability earns a score of 67/100, reflecting efficient cost management and pricing power. This is down from 15.3% the prior year.

Growth

CONMED Corporation's revenue grew 5.2% year-over-year to $1.4B, a solid pace of expansion. This earns a growth score of 50/100.

Leverage

CONMED Corporation has elevated debt relative to equity (D/E of 0.81), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 11/100, reflecting increased financial risk.

Liquidity

CONMED Corporation's current ratio of 2.14 indicates adequate short-term liquidity, earning a score of 62/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

CONMED Corporation converts 11.0% of revenue into free cash flow ($150.9M). This strong cash generation earns a score of 68/100.

Returns

CONMED Corporation's ROE of 4.6% shows moderate profitability relative to equity, earning a score of 58/100. This is down from 13.8% the prior year.

Altman Z-Score Grey Zone

1.93

CONMED Corporation scores 1.93, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

6/9

CONMED Corporation passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

3.62x

For every $1 of reported earnings, CONMED Corporation generates $3.62 in operating cash flow ($170.7M OCF vs $47.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

3.30x

CONMED Corporation earns $3.30 in operating income for every $1 of interest expense ($102.6M vs $31.1M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$343.5M

YoY+0.3%

CONMED Corporation generated $343.5M in revenue in Q2 2026. This represents an increase of 0.3% from the same quarter a year earlier.

Net Income

$23.1M

YoY+7.7%

CONMED Corporation reported $23.1M in net income in Q2 2026. This represents an increase of 7.7% from the same quarter a year earlier.

EPS (Diluted)

$0.77

YoY+11.6%

QoQ+42.6%

CONMED Corporation earned $0.77 per diluted share (EPS) in Q2 2026. This represents an increase of 11.6% from the same quarter a year earlier. Against the prior quarter it is up 42.6%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$37.3M

YoY+10.0%

QoQ-8.5%

CONMED Corporation held $37.3M in cash against $657.0M in long-term debt as of Q2 2026.

Shares Outstanding

30M

YoY-3.2%

QoQ-2.9%

5Y CAGR+0.6%

10Y CAGR+0.8%

CONMED Corporation had 30M shares outstanding in Q2 2026. This represents a decrease of 3.2% from the same quarter a year earlier. Against the prior quarter it is down 2.9%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

57.5%

YoY+2.5pp

CONMED Corporation's gross margin was 57.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.5 percentage points from the same quarter a year earlier.

Operating Margin

10.6%

YoY-0.6pp

CONMED Corporation's operating margin was 10.6% in Q2 2026, reflecting core business profitability. This is down 0.6 percentage points from the same quarter a year earlier.

Net Margin

6.7%

YoY+0.5pp

CONMED Corporation's net profit margin was 6.7% in Q2 2026, showing the share of revenue converted to profit. This is up 0.5 percentage points from the same quarter a year earlier.

Return on Equity

2.2%

YoY+0.1pp

CONMED Corporation's ROE was 2.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.1 percentage points from the same quarter a year earlier.

Capital Allocation

R&D Spending

$15.5M

YoY+9.6%

CONMED Corporation invested $15.5M in research and development in Q2 2026. This represents an increase of 9.6% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

CNMD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CNMD quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$1.4B+5.2%	$1.3B+5.0%	$1.2B+19.1%	$1.0B+3.4%	$1.0B+17.2%	$862.5M-9.7%	$955.1M+11.1%	$859.6M+7.9%	$796.4M+4.3%	$763.5M+6.2%	$719.2M-2.8%	$740.1M-3.0%	$762.7M-0.6%	$767.1M+5.8%	$725.1M
Cost of Revenue	$624.2M+8.8%	$574.0M+1.0%	$568.5M+19.9%	$474.2M+7.1%	$442.6M+10.1%	$402.2M-6.6%	$430.4M+10.2%	$390.5M+6.9%	$365.4M+2.9%	$355.2M+5.3%	$337.5M+0.4%	$336.0M-4.1%	$350.3M-3.0%	$361.3M+3.2%	$350.1M
Gross Profit	$750.5M+2.4%	$733.0M+8.4%	$676.2M+18.4%	$571.2M+0.6%	$568.0M+23.4%	$460.3M-12.3%	$524.7M+11.9%	$469.1M+8.8%	$431.0M+5.6%	$408.3M+7.0%	$381.7M-5.5%	$404.1M-2.0%	$412.4M+1.6%	$405.8M+8.2%	$374.9M
R&D Expenses	$55.9M+2.7%	$54.4M+3.5%	$52.6M+11.6%	$47.2M+8.2%	$43.6M+7.6%	$40.5M-11.0%	$45.5M+7.8%	$42.2M+30.6%	$32.3M+0.2%	$32.3M+17.6%	$27.4M-1.2%	$27.8M+7.5%	$25.8M-8.4%	$28.2M-1.5%	$28.7M
SG&A Expenses	$592.0M+23.8%	$478.3M-4.9%	$503.0M+10.8%	$454.0M+9.5%	$414.8M+11.0%	$373.8M-6.6%	$400.1M+12.5%	$355.6M+1.1%	$351.8M+4.0%	$338.4M+11.6%	$303.1M-6.3%	$323.5M-2.0%	$330.1M+9.1%	$302.5M+9.3%	$276.6M
Operating Income	$102.6M-48.8%	$200.3M+66.1%	$120.6M+72.2%	$70.1M-36.2%	$109.7M+138.5%	$46.0M-41.8%	$79.1M+11.0%	$71.3M+51.9%	$46.9M+24.6%	$37.7M-26.4%	$51.2M-3.1%	$52.8M-6.6%	$56.5M-13.3%	$65.2M+688.1%	$8.3M
EBITDA	$155.3M-38.4%	$252.0M+46.2%	$172.3M+43.4%	$120.2M-24.8%	$159.9M+62.2%	$98.6M-24.3%	$130.3M+15.3%	$113.0M+28.0%	$88.3M+13.0%	$78.2M-5.2%	$82.5M-3.6%	$85.6M-3.7%	$88.9M-9.0%	$97.6M+264.4%	$26.8M
Interest Expense	$31.1M-16.7%	$37.3M-6.2%	$39.8M+37.6%	$28.9M-18.5%	$35.5M-19.4%	$44.1M+3.2%	$42.7M+106.8%	$20.7M+13.5%	$18.2M+18.5%	$15.4M+154.7%	$6.0M-1.3%	$6.1M+8.9%	$5.6M-2.0%	$5.7M-14.2%	$6.7M
Income Tax	$24.1M-21.4%	$30.6M+87.0%	$16.4M+68.4%	$9.7M-8.0%	$10.6M+233.5%	-$7.9M-403.8%	$2.6M-73.4%	$9.8M+136.6%	-$26.8M-667.9%	$4.7M-67.8%	$14.6M+1.1%	$14.5M-1.4%	$14.7M-22.7%	$19.0M+721.5%	-$3.1M
Net Income	$47.1M-64.4%	$132.4M+105.3%	$64.5M+180.0%	-$80.6M-229.0%	$62.5M+556.7%	$9.5M-66.7%	$28.6M-29.9%	$40.9M-26.4%	$55.5M+278.4%	$14.7M-51.9%	$30.5M-5.3%	$32.2M-10.4%	$35.9M-11.2%	$40.5M+5283.1%	$752K
EPS (Basic)	$1.52-64.6%	$4.29+104.3%	$2.10+178.4%	-$2.68-225.2%	$2.14+548.5%	$0.33-67.3%	$1.01-30.3%	$1.45-27.1%	$1.99+275.5%	$0.53-51.8%	$1.10-6.0%	$1.17-10.0%	$1.30-9.1%	$1.43+4666.7%	$0.03
EPS (Diluted)	$1.51-64.5%	$4.25+108.3%	$2.04+176.1%	-$2.68-238.1%	$1.94+506.2%	$0.32-67.0%	$0.97-31.2%	$1.41-28.4%	$1.97+278.8%	$0.52-52.3%	$1.09-6.0%	$1.16-9.4%	$1.28-9.2%	$1.41+4600.0%	$0.03
Diluted Shares (Avg)	31M0.0%	31M-1.3%	32M+5.0%	30M-6.8%	32M+9.3%	29M-0.1%	29M+2.1%	29M+2.6%	28M+0.7%	28M+0.4%	28M+0.3%	28M-1.2%	28M-1.9%	29M+0.1%	29M

Metric	Q2'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$343.5M+0.3%	N/A	$337.9M+6.7%	$342.3M+3.1%	N/A	$345.9M+5.8%	$316.7M+4.0%	$332.1M+4.5%
Cost of Revenue	$146.0M-5.2%	N/A	$171.8M+24.8%	$154.0M+3.8%	N/A	$147.6M+1.9%	$137.7M+0.9%	$148.4M+1.0%
Gross Profit	$197.5M+4.9%	N/A	$166.1M-7.2%	$188.3M+2.5%	N/A	$198.3M+8.9%	$179.0M+6.5%	$183.7M+7.6%
R&D Expenses	$15.5M+9.6%	N/A	$13.9M+2.5%	$14.1M+0.3%	N/A	$13.2M-6.1%	$13.6M+8.8%	$14.1M+3.9%
SG&A Expenses	$145.6M+7.0%	N/A	$140.3M+40.7%	$136.0M+11.0%	N/A	$132.7M+12.5%	$99.7M-20.4%	$122.5M-5.5%
Operating Income	$36.4M-4.6%	N/A	$11.9M-81.9%	$38.2M-19.0%	N/A	$52.5M+4.6%	$65.7M+116.9%	$47.1M+71.8%
EBITDA	N/A	N/A	$25.0M-68.3%	N/A	N/A	$65.8M+3.6%	$78.7M+83.3%	$59.9M+48.3%
Interest Expense	$7.9M+0.8%	N/A	$7.6M-17.8%	$7.8M-18.4%	N/A	$8.9M-6.8%	$9.3M-7.7%	$9.6M-4.0%
Income Tax	$8.3M-2.6%	N/A	$1.4M-81.1%	$8.5M+12.7%	N/A	$9.9M+29.9%	$7.5M+68.1%	$7.5M+104.3%
Net Income	$23.1M+7.7%	N/A	$2.9M-94.2%	$21.4M-28.5%	N/A	$33.7M+1.9%	$49.0M+209.3%	$30.0M+118.3%
EPS (Basic)	$0.77+11.6%	$0.54-50.5%	$0.09-94.3%	$0.69-28.9%	N/A	$1.09+0.9%	$1.59+205.8%	$0.97+115.6%
EPS (Diluted)	$0.77+11.6%	$0.54-50.0%	$0.09-94.3%	$0.69-28.1%	N/A	$1.08+2.9%	$1.57+214.0%	$0.96+123.3%
Diluted Shares (Avg)	30M-3.0%	N/A	31M-0.2%	31M-0.2%	N/A	N/A	31M-1.8%	31M-2.2%

CNMD Balance Sheet

CNMD quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$2.3B+0.8%	$2.3B+0.3%	$2.3B+0.1%	$2.3B+30.1%	$1.8B+0.8%	$1.8B-1.3%	$1.8B+29.7%	$1.4B+0.8%	$1.4B+2.2%	$1.3B+20.6%	$1.1B+0.3%	$1.1B+0.7%	$1.1B+1.1%	$1.1B+15.3%	$935.6M
Current Assets	$672.9M+5.1%	$640.0M+4.0%	$615.6M+5.9%	$581.2M+26.3%	$460.1M+10.4%	$416.7M+4.9%	$397.4M+6.1%	$374.4M+4.9%	$356.8M+7.9%	$330.5M-8.1%	$359.8M-5.6%	$381.1M+2.4%	$372.1M+6.7%	$348.9M-2.2%	$356.7M
Cash & Equivalents	$40.8M+66.9%	$24.5M+0.7%	$24.3M-16.1%	$28.9M+38.8%	$20.8M-23.8%	$27.4M+5.8%	$25.9M+47.7%	$17.5M-46.3%	$32.6M+18.9%	$27.4M-62.2%	$72.5M+9.3%	$66.3M+21.8%	$54.4M+129.5%	$23.7M-8.9%	$26.0M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$355.5M+2.5%	$346.7M+8.9%	$318.3M-4.2%	$332.3M+43.5%	$231.6M+18.9%	$194.9M+18.4%	$164.6M+6.5%	$154.6M+9.3%	$141.4M+4.1%	$135.9M+1.9%	$133.4M-10.0%	$148.1M+3.4%	$143.2M-8.3%	$156.2M-7.2%	$168.4M
Accounts Receivable	$247.8M+4.2%	$237.7M-1.9%	$242.3M+26.6%	$191.3M+4.1%	$183.9M+3.8%	$177.2M-6.3%	$189.1M+4.2%	$181.6M+8.7%	$167.0M+12.7%	$148.2M+10.7%	$133.9M+3.5%	$129.3M-7.9%	$140.4M+0.9%	$139.1M+2.6%	$135.6M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$807.0M+0.2%	$805.4M-0.2%	$806.8M-1.1%	$815.4M+32.0%	$617.5M-0.1%	$618.4M+0.1%	$618.0M+54.3%	$400.4M-0.4%	$402.0M+1.1%	$397.7M+52.6%	$260.7M+1.7%	$256.2M+3.1%	$248.4M0.0%	$248.5M+5.8%	$234.8M
Total Liabilities	$1.3B-3.8%	$1.3B-8.3%	$1.5B-5.6%	$1.6B+58.3%	$980.6M-6.0%	$1.0B-2.1%	$1.1B+50.6%	$706.9M-2.7%	$726.5M-2.9%	$748.4M+44.9%	$516.6M-0.1%	$516.9M+6.8%	$484.2M+2.6%	$471.9M+30.2%	$362.5M
Current Liabilities	$315.0M+13.3%	$278.1M-10.5%	$310.7M+4.8%	$296.6M+50.8%	$196.6M+3.4%	$190.2M+1.1%	$188.1M+16.9%	$160.9M+7.3%	$150.0M+31.6%	$114.0M-4.8%	$119.7M+3.2%	$116.0M+4.2%	$111.3M-11.1%	$125.2M-4.6%	$131.2M
Non-Current Liabilities	$977.6M-8.2%	$1.1B-7.8%	$1.2B-8.0%	$1.3B+60.2%	$783.9M-8.0%	$852.4M-2.8%	$876.5M+60.6%	$545.9M-5.3%	$576.5M-9.1%	$634.5M+59.8%	$396.9M-1.0%	$400.9M+7.5%	$372.9M+7.6%	$346.6M+49.8%	$231.3M
Long-Term Debt	$834.2M-7.8%	$905.1M-7.0%	$973.1M-1.2%	$985.1M+46.5%	$672.4M-8.5%	$735.2M-2.6%	$755.2M+72.2%	$438.6M-7.0%	$471.7M-3.4%	$488.3M+81.2%	$269.5M+12.2%	$240.2M+12.0%	$214.4M+33.4%	$160.8M+80.8%	$89.0M
Total Equity	$1.0B+7.3%	$962.7M+15.4%	$834.2M+11.9%	$745.5M-5.1%	$785.4M+10.8%	$709.0M-0.2%	$710.5M+7.3%	$662.3M+4.9%	$631.4M+8.8%	$580.6M-0.8%	$585.1M+0.6%	$581.3M-4.1%	$606.3M-0.1%	$607.0M+5.9%	$573.1M
Retained Earnings	$588.8M+5.1%	$560.3M+23.8%	$452.5M+9.7%	$412.6M-16.9%	$496.6M+8.6%	$457.4M-2.9%	$470.8M+1.3%	$464.9M+5.6%	$440.1M+8.1%	$406.9M-1.8%	$414.5M+2.1%	$406.1M+2.6%	$395.9M+4.8%	$377.9M+6.6%	$354.4M

Metric	Q2'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$2.3B-1.2%	$2.3B+0.8%	$2.3B+0.3%	$2.3B+1.9%	$2.3B-0.5%	$2.3B+0.3%	$2.3B-0.4%	$2.3B-1.6%
Current Assets	$675.7M+2.7%	$672.9M+5.1%	$662.2M+3.3%	$657.8M+5.4%	$639.0M+0.5%	$640.0M+4.0%	$641.0M+2.5%	$623.8M+1.4%
Cash & Equivalents	$37.3M+10.0%	$40.8M+66.9%	$38.9M+1.2%	$33.9M+17.5%	N/A	$24.5M+0.7%	$38.5M+26.1%	$28.9M+3.7%
Short-Term Investments	$0	$0	$0	$0	N/A	$0	$0	$0
Inventory	$360.2M-0.6%	$355.5M+2.5%	$364.4M+6.4%	$362.3M+12.4%	$354.7M+10.0%	$346.7M+8.9%	$342.6M+5.1%	$322.4M-1.5%
Accounts Receivable	$239.8M+2.4%	$247.8M+4.2%	$224.9M-2.7%	$234.1M-2.1%	$221.1M-8.4%	$237.7M-1.9%	$231.2M+0.4%	$239.2M+4.3%
Long-Term Investments	$0	$0	$0	$0	N/A	$0	$0	$0
Goodwill	$796.9M-1.2%	$807.0M+0.2%	$806.9M0.0%	$806.9M+0.1%	$805.7M-0.1%	$805.4M-0.2%	$806.9M-1.0%	$806.2M-1.2%
Total Liabilities	$1.3B-5.0%	$1.3B-3.8%	$1.3B-5.0%	$1.3B-5.6%	$1.3B-9.2%	$1.3B-8.3%	$1.4B-9.6%	$1.4B-9.0%
Current Liabilities	$455.4M+54.5%	$315.0M+13.3%	$314.7M+11.5%	$294.8M+10.7%	$283.1M-2.8%	$278.1M-10.5%	$282.3M-25.0%	$266.4M-24.6%
Non-Current Liabilities	$803.5M-22.0%	$977.6M-8.2%	$999.5M-9.2%	$1.0B-9.4%	$1.0B-10.9%	$1.1B-7.8%	$1.1B-4.6%	$1.1B-4.4%
Long-Term Debt	$657.0M-25.4%	$834.2M-7.8%	$853.0M-9.3%	$881.1M-8.7%	$891.4M-10.0%	$905.1M-7.0%	$940.1M-0.2%	$965.2M-0.6%
Total Equity	$1.0B+3.8%	$1.0B+7.3%	$1.0B+8.1%	$1.0B+13.7%	$977.6M+14.4%	$962.7M+15.4%	$932.9M+17.2%	$881.8M+13.0%
Retained Earnings	$625.7M+8.7%	$588.8M+5.1%	$572.0M+7.4%	$575.4M+17.4%	$560.1M+20.2%	$560.3M+23.8%	$532.7M+25.2%	$489.9M+17.8%

CNMD Cash Flow Statement

CNMD quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$170.7M+2.2%	$167.0M+33.2%	$125.3M+275.7%	$33.4M-70.1%	$111.8M+73.2%	$64.5M-32.2%	$95.1M+27.4%	$74.7M+13.9%	$65.6M+64.4%	$39.9M-21.7%	$50.9M-21.9%	$65.2M-19.5%	$80.9M-15.0%	$95.2M-7.6%	$103.0M
Depreciation & Amortization	$52.7M+2.0%	$51.7M-0.1%	$51.7M+3.2%	$50.2M-0.1%	$50.2M-4.6%	$52.6M+2.7%	$51.2M+22.8%	$41.7M+0.8%	$41.4M+2.2%	$40.5M+29.3%	$31.3M-4.5%	$32.8M+1.4%	$32.4M-0.3%	$32.4M+75.1%	$18.5M
Stock-Based Compensation	$28.3M+10.8%	$25.6M+5.4%	$24.3M+11.6%	$21.7M+33.0%	$16.3M+24.6%	$13.1M+11.3%	$11.8M+17.4%	$10.0M+18.5%	$8.5M+1.2%	$8.4M+11.7%	$7.5M-19.6%	$9.3M+66.8%	$5.6M-1.1%	$5.7M+7.9%	$5.2M
Capital Expenditures	$19.8M+51.4%	$13.1M-31.3%	$19.0M-12.6%	$21.8M+46.5%	$14.9M+14.2%	$13.0M-35.1%	$20.1M+21.6%	$16.5M+28.5%	$12.8M-13.0%	$14.8M-1.7%	$15.0M-2.6%	$15.4M-16.4%	$18.4M-14.3%	$21.5M+22.7%	$17.6M
Free Cash Flow	$150.9M-2.0%	$153.9M+44.7%	$106.3M+818.1%	$11.6M-88.1%	$96.9M+88.1%	$51.5M-31.4%	$75.1M+29.0%	$58.2M+10.4%	$52.7M+109.8%	$25.1M-30.0%	$35.9M-27.8%	$49.8M-20.4%	$62.5M-15.2%	$73.7M-13.8%	$85.4M
Investing Cash Flow	-$21.0M-60.2%	-$13.1M+34.7%	-$20.0M+92.0%	-$249.5M-1578.5%	-$14.9M-9.0%	-$13.6M+96.5%	-$387.7M-2248.5%	-$16.5M+43.2%	-$29.1M+89.1%	-$266.0M-992.0%	-$24.4M-17.8%	-$20.7M-12.1%	-$18.4M+82.6%	-$105.9M-387.3%	-$21.7M
Financing Cash Flow	-$135.8M+10.1%	-$151.0M-36.7%	-$110.4M-149.1%	$225.0M+321.6%	-$101.5M-95.1%	-$52.1M-117.3%	$300.9M+516.4%	-$72.3M-107.2%	-$34.9M-119.1%	$182.5M+1546.2%	-$12.6M+52.2%	-$26.4M+15.7%	-$31.3M-375.7%	$11.4M+117.0%	-$66.7M
Dividends Paid	$24.7M+0.4%	$24.7M+0.6%	$24.5M+2.3%	$24.0M+3.0%	$23.3M+1.9%	$22.8M+1.0%	$22.6M+0.7%	$22.4M+0.6%	$22.3M+0.4%	$22.2M+0.5%	$22.1M+0.7%	$22.0M+31.5%	$16.7M+29.8%	$12.9M	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$16.9M-66.6%	$50.6M+1188.7%	$3.9M-73.9%	$15.0M

Metric	Q2'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	N/A	$46.3M+6.9%	$53.7M+4.8%	N/A	N/A	$43.3M-23.2%	$51.2M+11.0%	$43.3M+62.4%
Depreciation & Amortization	N/A	$13.2M+2.1%	$13.1M+0.6%	N/A	N/A	$12.9M-0.4%	$13.0M+2.9%	$12.8M-1.5%
Stock-Based Compensation	$5.2M+6.7%	N/A	$4.6M-25.1%	$4.9M-29.7%	N/A	N/A	$6.1M	$7.0M
Capital Expenditures	N/A	$5.1M+26.5%	$5.2M+51.7%	N/A	N/A	$4.0M-16.8%	$3.4M-36.6%	$3.6M-20.7%
Free Cash Flow	N/A	$41.2M+4.9%	$48.5M+1.5%	N/A	N/A	$39.3M-23.8%	$47.8M+17.3%	$39.7M+79.4%
Investing Cash Flow	N/A	-$7.1M-76.0%	-$5.2M-51.7%	N/A	N/A	-$4.0M+16.8%	-$3.4M+36.6%	-$3.6M+35.1%
Financing Cash Flow	N/A	-$37.4M+26.8%	-$43.5M-12.1%	N/A	N/A	-$51.1M+13.1%	-$38.8M-4.3%	-$44.1M-122.8%
Dividends Paid	N/A	$6.2M+0.2%	$6.2M+0.4%	N/A	N/A	$6.2M+0.5%	$6.2M+0.3%	$6.2M+0.8%

Not reported in any period shown, so not listed: Share Buybacks.

CNMD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CNMD quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	54.6%-1.5pp	56.1%+1.7pp	54.3%-0.3pp	54.6%-1.6pp	56.2%+2.8pp	53.4%-1.6pp	54.9%+0.4pp	54.6%+0.4pp	54.1%+0.6pp	53.5%+0.4pp	53.1%-1.5pp	54.6%+0.5pp	54.1%+1.2pp	52.9%+1.2pp	51.7%
Operating Margin	7.5%-7.9pp	15.3%+5.6pp	9.7%+3.0pp	6.7%-4.2pp	10.9%+5.5pp	5.3%-2.9pp	8.3%0.0pp	8.3%+2.4pp	5.9%+1.0pp	4.9%-2.2pp	7.1%0.0pp	7.1%-0.3pp	7.4%-1.1pp	8.5%+7.4pp	1.1%
Net Margin	3.4%-6.7pp	10.1%+5.0pp	5.2%+12.9pp	-7.7%-13.9pp	6.2%+5.1pp	1.1%-1.9pp	3.0%-1.8pp	4.8%-2.2pp	7.0%+5.1pp	1.9%-2.3pp	4.2%-0.1pp	4.3%-0.4pp	4.7%-0.6pp	5.3%+5.2pp	0.1%
Return on Equity	4.6%-9.2pp	13.8%+6.0pp	7.7%+18.5pp	-10.8%-18.8pp	8.0%+6.6pp	1.3%-2.7pp	4.0%-2.1pp	6.2%-2.6pp	8.8%+6.3pp	2.5%-2.7pp	5.2%-0.3pp	5.5%-0.4pp	5.9%-0.7pp	6.7%+6.5pp	0.1%
Return on Assets	2.0%-3.7pp	5.7%+2.9pp	2.8%+6.3pp	-3.5%-7.1pp	3.5%+3.0pp	0.5%-1.1pp	1.6%-1.4pp	3.0%-1.1pp	4.1%+3.0pp	1.1%-1.7pp	2.8%-0.2pp	2.9%-0.4pp	3.3%-0.4pp	3.8%+3.7pp	0.1%
Current Ratio	2.14-0.2x	2.30+0.3x	1.980.0x	1.96-0.4x	2.34+0.1x	2.19+0.1x	2.11-0.2x	2.33-0.1x	2.38-0.5x	2.90-0.1x	3.01-0.3x	3.29-0.1x	3.34+0.6x	2.79+0.1x	2.72
Debt-to-Equity	0.81-0.1x	0.94-0.2x	1.17-0.2x	1.32+0.5x	0.86-0.2x	1.040.0x	1.06+0.4x	0.66-0.1x	0.75-0.1x	0.84+0.4x	0.460.0x	0.41+0.1x	0.35+0.1x	0.26+0.1x	0.16
Asset Turnover	0.590.0x	0.570.0x	0.54+0.1x	0.46-0.1x	0.57+0.1x	0.490.0x	0.54-0.1x	0.630.0x	0.590.0x	0.57-0.1x	0.650.0x	0.670.0x	0.700.0x	0.71-0.1x	0.78
FCF Margin	11.0%-0.8pp	11.8%+3.2pp	8.5%+7.4pp	1.1%-8.5pp	9.6%+3.6pp	6.0%-1.9pp	7.9%+1.1pp	6.8%+0.2pp	6.6%+3.3pp	3.3%-1.7pp	5.0%-1.7pp	6.7%-1.5pp	8.2%-1.4pp	9.6%-2.2pp	11.8%

Metric	Q2'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Gross Margin	57.5%+2.5pp	N/A	49.2%-7.4pp	55.0%-0.3pp	N/A	57.3%+1.6pp	56.5%+1.3pp	55.3%+1.6pp
Operating Margin	10.6%-0.6pp	N/A	3.5%-17.2pp	11.2%-3.0pp	N/A	15.2%-0.2pp	20.8%+10.8pp	14.2%+5.6pp
Net Margin	6.7%+0.5pp	N/A	0.9%-14.6pp	6.3%-2.8pp	N/A	9.8%-0.4pp	15.5%+10.3pp	9.0%+4.7pp
Return on Equity	2.2%+0.1pp	N/A	0.3%-5.0pp	2.1%-1.3pp	N/A	3.5%-0.5pp	5.3%+3.3pp	3.4%+1.6pp
Return on Assets	1.0%+0.1pp	N/A	0.1%-2.0pp	0.9%-0.4pp	N/A	1.5%0.0pp	2.1%+1.4pp	1.3%+0.7pp
Current Ratio	1.48-0.7x	2.14-0.2x	2.10-0.2x	2.23-0.1x	2.26+0.1x	2.30+0.3x	2.27+0.6x	2.34+0.6x
Debt-to-Equity	0.63-0.2x	0.81-0.1x	0.85-0.2x	0.88-0.2x	0.91-0.2x	0.94-0.2x	1.01-0.2x	1.09-0.2x
Asset Turnover	0.150.0x	N/A	0.150.0x	0.150.0x	N/A	0.150.0x	0.140.0x	0.150.0x
FCF Margin	N/A	N/A	14.3%-0.7pp	N/A	N/A	11.4%-4.4pp	15.1%+1.7pp	12.0%+5.0pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
CONMED Corporation CNMD	FY2025	$1.4B	$47.1M	3.4%	$1.4B	53/100
Enovis Corporation ENOV	FY2025	$2.2B	-$1.2B	-52.7%	$1.1B	34/100
UFP Technologies Inc UFPT	FY2025	$602.8M	$68.3M	11.3%	$2.2B	72/100
Artivion, Inc. AORT	FY2025	$441.3M	$9.8M	2.2%	$1.2B	49/100
NovoCure Limited NVCR	FY2025	$655.4M	-$136.2M	-20.8%	$1.9B	63/100
SS Innovations International Inc. SSII	FY2025	$42.5M	-$12.1M	-28.5%	$678.3M	38/100

Where CONMED Corporation Ranks

Frequently Asked Questions

What is CONMED Corporation's annual revenue?

CONMED Corporation (CNMD) reported $1.4B in total revenue for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is CONMED Corporation's revenue growing?

CONMED Corporation (CNMD) revenue grew by 5.2% year-over-year, from $1.3B to $1.4B in fiscal year 2025.

Is CONMED Corporation profitable?

Yes, CONMED Corporation (CNMD) reported a net income of $47.1M in fiscal year 2025, with a net profit margin of 3.4%.

What is CONMED Corporation's EBITDA?

CONMED Corporation (CNMD) had EBITDA of $155.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does CONMED Corporation have?

As of fiscal year 2025, CONMED Corporation (CNMD) had $40.8M in cash and equivalents against $834.2M in long-term debt.

What is CONMED Corporation's gross margin?

CONMED Corporation (CNMD) had a gross margin of 54.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is CONMED Corporation's operating margin?

CONMED Corporation (CNMD) had an operating margin of 7.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is CONMED Corporation's net profit margin?

CONMED Corporation (CNMD) had a net profit margin of 3.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does CONMED Corporation pay dividends?

Yes, CONMED Corporation (CNMD) paid $0.60 per share in dividends during fiscal year 2025.

What is CONMED Corporation's return on equity (ROE)?

CONMED Corporation (CNMD) has a return on equity of 4.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is CONMED Corporation's free cash flow?

CONMED Corporation (CNMD) generated $150.9M in free cash flow during fiscal year 2025. This represents a -2.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is CONMED Corporation's operating cash flow?

CONMED Corporation (CNMD) generated $170.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are CONMED Corporation's total assets?

CONMED Corporation (CNMD) had $2.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are CONMED Corporation's capital expenditures?

CONMED Corporation (CNMD) invested $19.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does CONMED Corporation spend on research and development?

CONMED Corporation (CNMD) invested $55.9M in research and development during fiscal year 2025.

How many shares does CONMED Corporation have outstanding?

CONMED Corporation (CNMD) had 31M shares outstanding as of fiscal year 2025.

What is CONMED Corporation's current ratio?

CONMED Corporation (CNMD) had a current ratio of 2.14 as of fiscal year 2025, which is generally considered healthy.

What is CONMED Corporation's debt-to-equity ratio?

CONMED Corporation (CNMD) had a debt-to-equity ratio of 0.81 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is CONMED Corporation's return on assets (ROA)?

CONMED Corporation (CNMD) had a return on assets of 2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is CONMED Corporation's P/E ratio?

CONMED Corporation (CNMD) trades at 29.9x earnings, its market capitalization divided by net income of $47.1M net income, FY2025. The market capitalization is $1.4B as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is CONMED Corporation's price-to-sales ratio?

CONMED Corporation (CNMD) trades at 1.0x sales, its market capitalization divided by revenue of $1.4B revenue, FY2025. The market capitalization is $1.4B as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is CONMED Corporation's Altman Z-Score?

CONMED Corporation (CNMD) has an Altman Z-Score of 1.93, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is CONMED Corporation's Piotroski F-Score?

CONMED Corporation (CNMD) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are CONMED Corporation's earnings high quality?

CONMED Corporation (CNMD) has an earnings quality ratio of 3.62x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can CONMED Corporation cover its interest payments?

CONMED Corporation (CNMD) has an interest coverage ratio of 3.30x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is CONMED Corporation?

CONMED Corporation (CNMD) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.